[go: up one dir, main page]

ES2137158T3 - N-bencil-indoles, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

N-bencil-indoles, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2137158T3
ES2137158T3 ES91306940T ES91306940T ES2137158T3 ES 2137158 T3 ES2137158 T3 ES 2137158T3 ES 91306940 T ES91306940 T ES 91306940T ES 91306940 T ES91306940 T ES 91306940T ES 2137158 T3 ES2137158 T3 ES 2137158T3
Authority
ES
Spain
Prior art keywords
elevated
sub
alkyl
hydrogen
elevado
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91306940T
Other languages
English (en)
Inventor
Jeremy Gilmore
Alec Todd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co Ltd
Eli Lilly and Co
Original Assignee
Eli Lilly and Co Ltd
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909016790A external-priority patent/GB9016790D0/en
Priority claimed from GB919107486A external-priority patent/GB9107486D0/en
Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd
Application granted granted Critical
Publication of ES2137158T3 publication Critical patent/ES2137158T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

UN COMPUESTO DE LA FORMULA EN LA CUAL R ELEVADO 1 ES HIDROGENO, HALO, ALQUILO C SUB 1-4, ALCOXI C SUB 1-4, NITRILO, CARBOXI OPCIONALMENTE PROTEGIDO, TETRAZOILO OPCIONALMENTE PROTEGIDO, TRIALOMETILO, HIDROXI-ALQUILO-C SUB 1-4, ALDEHIDO, -CH SUB 2Z, -CH=CH-Z O LMENTE PROTEGIDO O TETRAZOILO OPCIONALMENTE PROTEGIDO; R (AL CUADRADO) ES HALO, NITRILO, Y UN GRUPO ACIDO OPCIONALMENTE PROTEGIDO O -CONR ELEVADO 7R ELEVADO 8 DONDE R ELEVADO 7 Y R ELEVADO 8 SON CADA UNA HIDROGENO O ALQUILO C SUB 1-4, FENILO OPCIONALMENTE SUSTITUIDO, O ALQUILO C SUB 1-4 SUSTITUIDO POR -CONR ELEVADO 7R ELEVADO 8 O UN GRUPO ACIDO OPCIONALMENTE PROTEGIDO; R ELEVADO 5 ES DONDE W ES -CH=CH-, R ELEVADO 9 ES HIDROGENO, HALO, ALQUILO C SUB 1-4, ALCOXI C SUB 1-4, ALQUENILO C SUB 2-6, CICLOALQUILO C SUB 3-6 O CICLOALQUILO C SUB 3-6-ALQUILO C SUB 1-4; R ELEVADO 6 ES HIDROGENO O ALQUILO C SUB 1-4; X ES -O-(CH SUB 2) SUB N CR ELEVADO 11CR ELEVADO 12-, -CR ELEVADO 11R ELEVADO 12-, -CR ELEVADO 11R ELEVADO 12(CH SUB 2) SUB 1 . CR ELEVADO 13R ELEVADO 14 =CR ELEVADO 12 Y R ELEVADO 14 SON CADA UNA HIDROGENO O ALQUILO C SUB 1-4, Y N ES 0, 1 O 2; E Y ES -O-CR ELEVADO 15R ELEVADO 16-, -CR ELEVADO 15=CR ELEVADO 16 ADO 16 . CR ELEVADO 17R ELEVADO 18ADO 16, R ELEVADO 17 Y R ELEVADO 18 SON CADA UNA HIDROGENO O ALQUILO C SUB 1-4; O UNA SAL DE ESTO. LOS COMPUESTOS EN FORMA DESPROTEGIDA SON ACTIVOS COMO ANTAGONISTAS LEUCOTRIENOS.
ES91306940T 1990-07-31 1991-07-29 N-bencil-indoles, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2137158T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909016790A GB9016790D0 (en) 1990-07-31 1990-07-31 Pharmaceutical compounds
GB919107486A GB9107486D0 (en) 1991-04-09 1991-04-09 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ES2137158T3 true ES2137158T3 (es) 1999-12-16

Family

ID=26297410

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91306940T Expired - Lifetime ES2137158T3 (es) 1990-07-31 1991-07-29 N-bencil-indoles, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (24)

Country Link
EP (1) EP0469833B1 (es)
JP (1) JP3220191B2 (es)
KR (1) KR0179985B1 (es)
CN (1) CN1040108C (es)
AT (1) ATE184280T1 (es)
AU (1) AU654140B2 (es)
CA (1) CA2048096C (es)
CZ (1) CZ279932B6 (es)
DE (1) DE69131592T2 (es)
DK (1) DK0469833T3 (es)
ES (1) ES2137158T3 (es)
FI (1) FI102536B (es)
GR (1) GR3032038T3 (es)
HU (2) HU213604B (es)
IE (1) IE912670A1 (es)
IL (1) IL98990A (es)
MX (1) MX9100414A (es)
MY (1) MY131141A (es)
NO (1) NO300133B1 (es)
NZ (1) NZ239168A (es)
PH (1) PH30487A (es)
PT (1) PT98475B (es)
SK (1) SK279197B6 (es)
YU (1) YU47839B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9122590D0 (en) * 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5416211A (en) * 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
US5486612A (en) * 1993-12-14 1996-01-23 Eli Lilly And Company N-benzyl dihydroindole LTD4 antagonists
EP0743064A1 (en) * 1995-05-17 1996-11-20 Eli Lilly And Company Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease
GB9523948D0 (en) * 1995-11-23 1996-01-24 Univ East Anglia Process for preparing n-benzyl indoles
US6160120A (en) * 1996-11-19 2000-12-12 Eli Lilly And Company Process for preparing n-benzyl indoles
MX2007004527A (es) * 2004-10-12 2007-09-21 Decode Genetics Inc Acidos carboxilicos biciclicos peri-sustituidos para enfermedad de arteria oclusiva.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
MY103259A (en) * 1987-04-15 1993-05-29 Ici America Inc Aliphatic carboxamides
GB8728051D0 (en) * 1987-12-01 1988-01-06 Leo Pharm Prod Ltd Chemical compounds
US4970207A (en) * 1988-07-07 1990-11-13 Fujisawa Pharmaceutical Company, Ltd. Benzodiazepine derivatives

Also Published As

Publication number Publication date
JP3220191B2 (ja) 2001-10-22
AU8139991A (en) 1992-02-06
CN1061413A (zh) 1992-05-27
AU654140B2 (en) 1994-10-27
YU47839B (sr) 1996-01-09
FI913639A0 (fi) 1991-07-30
HU912535D0 (en) 1992-01-28
HUT60491A (en) 1992-09-28
KR920002582A (ko) 1992-02-28
NO300133B1 (no) 1997-04-14
IE912670A1 (en) 1992-02-12
EP0469833B1 (en) 1999-09-08
ATE184280T1 (de) 1999-09-15
NO912963D0 (no) 1991-07-30
CA2048096C (en) 2002-09-17
DK0469833T3 (da) 1999-12-20
DE69131592T2 (de) 2000-01-20
HU211952A9 (en) 1996-01-29
GR3032038T3 (en) 2000-03-31
IL98990A (en) 1995-06-29
PT98475B (pt) 1997-11-28
CN1040108C (zh) 1998-10-07
CS238091A3 (en) 1992-03-18
FI913639A7 (fi) 1992-02-01
MX9100414A (es) 1992-02-28
NO912963L (no) 1992-02-03
CZ279932B6 (cs) 1995-08-16
PT98475A (pt) 1992-06-30
SK279197B6 (sk) 1998-07-08
KR0179985B1 (ko) 1999-03-20
FI102536B1 (fi) 1998-12-31
DE69131592D1 (de) 1999-10-14
YU132591A (sh) 1994-01-20
PH30487A (en) 1997-05-28
IL98990A0 (en) 1992-07-15
EP0469833A1 (en) 1992-02-05
MY131141A (en) 2007-07-31
HU213604B (en) 1997-08-28
FI102536B (fi) 1998-12-31
JPH06220045A (ja) 1994-08-09
NZ239168A (en) 1993-05-26
CA2048096A1 (en) 1992-02-01

Similar Documents

Publication Publication Date Title
ES542319A0 (es) Un procedimiento para la preparacion de derivados de la 2 pirimidinil-1-piperazina
ATE185558T1 (de) Prostaglandin-synthase hemmer
ES2043781T3 (es) Un procedimiento para la preparacion de nuevos derivados de 2beta-morfolino-androstano.
SE7614258L (sv) Forfarande for framstellning av kinazoloderivat
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
ES2137158T3 (es) N-bencil-indoles, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ATE20732T1 (de) Halogenierte proteaseinhibitoren.
DK607783D0 (da) Nitroaliphatiske forbindelser
EP0351385A3 (en) New amidino and guanidino derivatives
SE8306370D0 (sv) Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions
DK163144C (da) Diethylaminoalkoxybenzhydrolderivater og farmaceutisk acceptable syreadditionssalte og kvaternaere ammoniumsalte deraf, fremgangsmaade til fremstilling heraf, farmaceutisk praeparat og fremgangsmaade til fremstilling heraf
ES8501763A1 (es) "procedimiento para la fabricacion de derivados de la tetrahidro-5.6.7.7. 4h-tieno (3, 2-c) piridinona-2
ES8207505A1 (es) Procedimiento para la preparacion de derivados de fenoxi- aminopropanol substituidos
AU4906799A (en) Substituted benzimidazoles, production and use thereof as agents for combating parasitic protozoas
ES528459A0 (es) Procedimiento de preparacion de nuevos derivados 1-hidroxipropil resorcinos provistos de un grupo fenilo sustituidos.
FI833369A0 (fi) -aryl- -pyridylalkansyraderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutisk komposition
ES8504180A1 (es) Procedimiento para preparar nuevos derivados de piperidina
FR2795730B1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PE20020551A1 (es) Proceso para preparar derivados de distamicina
US4367341A (en) Antiatherosclerotic 7-substituted methoxyfurochromones
DK601983D0 (da) Aminoethoxybenzylalkoholderivater
ATE19629T1 (de) N-substituierte derivate des tetrahydroisophthalimids.
SE8405332L (sv) 2h-azeto (2,1-a)-isokinolinderivat, forfarande for deras framstellning och farmaceutiska kompositioner innehallande dem
ES534033A0 (es) Procedimiento para la preparacion de derivados de acridanona.
YU164991A (sh) Hidroksialkilhinolin etar kiseline kao antagonisti leukotriena

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 469833

Country of ref document: ES